Lumosa Therapeutics Co. Ltd.
6535.TWO
| Exchange: | TWO |
| Currency | New Taiwan Dollar |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Description: | Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan. |
| Address: | No. 3-2, Park Street, Taipei, Taiwan, 11503 |
| Website: | https://www.lumosa.com.tw |
| Full Time Employees: | 47 |
| Updated On: | 2024-11-09 |
Highlights
| Market Capitalization: | 57855700992 |
| Market Capitalization Mln: | 57855.70 |
| EBITDA: | -335080992 |
| Book Value: | 8.29 |
| Earnings Share: | -1.75 |
| Most Recent Quarter: | 2024-06-30 |
| Operating Margin TTM: | -8.58 |
| Return On Assets TTM: | -0.12 |
| Return On Equity TTM: | -0.19 |
| Revenue TTM: | 47713000 |
| Revenue Per Share TTM: | 0.29 |
| Quarterly Revenue Growth YOY: | -0.40 |
| Diluted Eps TTM: | -1.75 |
Valuation
| Price Sales TTM: | 1212.57 |
| Price Book MRQ: | 42.28 |
| Enterprise Value: | 57257210600 |
| Enterprise Value Revenue: | 1200.03 |
Shares
| Shares Outstanding: | 165302000 |
| Shares Float: | 89228117 |
| Percent Insiders: | 47.01 |
| Percent Institutions: | 5.20 |
Technicals
| Beta: | 0.35 |
| 52 Week High: | 400 |
| 52 Week Low: | 58.9 |
| 50 Day MA: | 301.89 |
| 200 Day MA: | 216.10 |
Earnings
| Report Date: | 2024-05-14 |
| Date: | 2024-03-31 |
| Before After Market: | After Market |
| Eps Actual: | -0.71 |
| Eps Estimate: | -0.61 |
| Eps Difference: | -0.1 |
| Surprise Percent: | -16.39 |
| Report Date: | 2017-05-12 |
| Date: | 2017-03-31 |
| Before After Market: | After Market |
| Eps Actual: | -0.62 |
| Eps Estimate: | -0.78 |
| Eps Difference: | 0.16 |
| Surprise Percent: | 20.51 |
| Report Date: | 2016-11-14 |
| Date: | 2016-09-30 |
| Before After Market: | After Market |
| Eps Actual: | -0.87 |
| Eps Estimate: | -0.75 |
| Eps Difference: | -0.12 |
| Surprise Percent: | -1 |
| Date: | 2024-03-31 |
| Eps Actual: | -2. |